Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 12/20 | 0.38 |
| ▸ | IDO1 | P14902 | 11/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25890747 | 0.95 | TDO2 (0.38) | TDO2IDO1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL25895953 | 0.83 | TDO2 (0.39) | TDO2IDO1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL23869690 | 0.82 | IDO1 (0.33) | TDO2IDO1SMN1; SMN2CES1TTR | |
| SCHEMBL25895952 | 0.81 | TOP2A (0.43) | TDO2IDO1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL25892503 | 0.78 | SMN1; SMN2 (0.31) | SMN1; SMN2HTTPOLB | |
| SCHEMBL23869733 | 0.77 | IDO1 (0.33) | TDO2IDO1SMN1; SMN2CES1TTR | |
| SCHEMBL24479357 | 0.72 | IDO1 (0.30) | TDO2IDO1 | |
| SCHEMBL20151895 | 0.72 | ALDH1A1 (0.44) | TDO2IDO1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL16980287 | 0.71 | CHRM2 (0.34) | TDO2IDO1ALDH1A1CES1BCHE | |
| SCHEMBL18272795 | 0.71 | TTR (0.49) | TDO2IDO1HPGDALDH1A1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | TDO2 1135/4885IDO1 177/4885SMN1; SMN2 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.